# Study of FID-022 in Participants With Advanced Solid Tumors

> **NCT06694480** · PHASE1 · RECRUITING · sponsor: **Fulgent Pharma LLC.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** FID-022

## Key facts

- **NCT ID:** NCT06694480
- **Lead sponsor:** Fulgent Pharma LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-03
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06694480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06694480, "Study of FID-022 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06694480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*